Literature DB >> 33994745

Functional Malignant Retroperitoneal Paraganglioma with Liver Metastasis: a Rare Case Report.

Sachin S Kadam1, Sujai Hegde2, Amol Galage3, Tejaswini Kadam4.   

Abstract

Paragangliomas are rare neoplasms. Their specific annual incidence is still unclear. These are rare neuroendocrine tumors which arise from extra-adrenal paraganglioma and they have the ability to secrete catecholamines. Most of them are diagnosed in the 3rd to 5th decades of life with mean age around 47 years. Majority of them are benign; however, malignant tumors with metastatic behavior are very rare. The incidence of malignant paraganglioma is estimated around 93/400 million people. The clinical course of metastatic malignant disease is variable and the reported 5-year survival is around 12-84%. There is no curative treatment option for malignant metastatic paraganglioma. If resectable, both, primary and metastasis should be resected. The only criteria which defines its malignancy is the presence of metastatic spread of chromaffin cells in tissues that normally do not contain such cells. Functional paraganglioma secretes excessive catecholamines which clinically manifest as paroxysmal hypertension, headache, sweating, and palpitations. We reported a case of young male who presented with huge left retroperitoneal mass and after evaluation found to have a functional malignant paraganglioma with liver metastasis. Surgical resection of the primary malignant paraganglioma with metastatectomy helps in decreasing the complications, improving the symptoms and prolonging the survival. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Catecholamine; Functional; Metastatic; Paraganglioma; Surgical resection

Year:  2021        PMID: 33994745      PMCID: PMC8119541          DOI: 10.1007/s13193-020-01259-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  18 in total

1.  177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

Authors:  Michael Garkavij; Mattias Nickel; Katarina Sjögreen-Gleisner; Michael Ljungberg; Tomas Ohlsson; Karin Wingårdh; Sven-Erik Strand; Jan Tennvall
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

2.  Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.

Authors:  C M Beard; S G Sheps; L T Kurland; J A Carney; J T Lie
Journal:  Mayo Clin Proc       Date:  1983-12       Impact factor: 7.616

Review 3.  Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (TACE).

Authors:  Satoshi Hidaka; Atsushi Hiraoka; Hironori Ochi; Takahide Uehara; Tomoyuki Ninomiya; Yasunao Miyamoto; Aki Hasebe; Tetsuya Tanihira; Atsushi Tanabe; Misa Ichiryu; Hiromasa Nakahara; Nayu Tazuya; Iku Ninomiya; Kojiro Michitaka
Journal:  Intern Med       Date:  2010-04-01       Impact factor: 1.271

Review 4.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.

Authors:  Jenny Welander; Peter Söderkvist; Oliver Gimm
Journal:  Endocr Relat Cancer       Date:  2011-12-01       Impact factor: 5.678

5.  Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.

Authors:  Veljko Strajina; Benzon M Dy; David R Farley; Melanie L Richards; Travis J McKenzie; Keith C Bible; Florencia G Que; David M Nagorney; William F Young; Geoffrey B Thompson
Journal:  Ann Surg Oncol       Date:  2017-01-05       Impact factor: 5.344

6.  Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients.

Authors:  D Erickson; Y C Kudva; M J Ebersold; G B Thompson; C S Grant; J A van Heerden; W F Young
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

7.  The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Authors:  Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

8.  PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma.

Authors:  Ingo Janssen; Clara C Chen; Corina M Millo; Alexander Ling; David Taieb; Frank I Lin; Karen T Adams; Katherine I Wolf; Peter Herscovitch; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236

9.  Posterior mediastinal paragangliomas: a report of three patients with peculiar tumours.

Authors:  Aïda Ayadi-Kaddour; Emna Braham; Olfa Ismail; Bellahssan Smati; Habiba Djilani; Faouzi El Mezni
Journal:  Respirology       Date:  2009-01-27       Impact factor: 6.424

10.  A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.

Authors:  Grainne M O'Kane; Shereen Ezzat; Anthony M Joshua; Isabelle Bourdeau; Raya Leibowitz-Amit; Harold J Olney; Monika Krzyzanowska; Dean Reuther; Soo Chin; Lisa Wang; Kelly Brooks; Aaron R Hansen; Sylvia L Asa; Jennifer J Knox
Journal:  Br J Cancer       Date:  2019-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.